Institut National De La Sante Et De La Recherche Medicale

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Université Cote D'azur

Chu De Nice

Centre National De La Recherche Scientifique

University De Nice Sophia Antipolis

Centre National De La Recherche Scientifique-Cnrs

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Centre Hospitalier Universitaire De Nice

Inserm

Thierry Passeron

Vincent J Hearing

Florence Joly

Yuji Yamaguchi

Rachid Benhida

Anthony Martin

Gian Marco De Donatis

Pascal Dao

Meri Tulic

De Donatis Gian Marco

The present invention relates to a compound of general formula (I), wherein Ris OCHCHOCHor OCH, R'is H or OH, Ris Cl, F, Br or I, with the proviso that when: Ris OCHCHOCHthen R′is H, Ris OCHthen R′is OH, its pharmaceutically acceptable salts and/or optical isomers, tautomers, solvates or isotopic variations thereof. The invention also relates to said compounds for use in the treatment of cancer, namely solid tumor cancer, and preferably those selected from melanoma, colon, lung, pancreas, kidney, Merkel carcinoma, squamous cell carcinoma, prostate, breast and bladder. The invention also relates to a pharmaceutical composition comprising said compounds.

Substituted halo-quinoline derivatives, method of preparation and applications thereof

The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.

Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders

The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.

GSK3B and uses thereof in the diagnostic and treatment of hypopigmentation disorders

A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject comprising administering an amount of inhibitor of SOX9 activity sufficient to treat the condition is disclosed. A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering an amount of prostaglandin D2 and retinoic acid sufficient to treat cancer is disclosed. A method of sensitizing a melanoma cell to RA comprising administering an amount of SOX9 sufficient to decrease PRAME expression is disclosed.

Compositions and methods for treating pigmentary conditions and melanoma

The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.

Treatment of skin conditions by Dickkopf1 (DKK1)

Regulation of skin characteristics by DICKKOPF1 (DKK1)

Growing community of inventors

Nice, France

Thierry Passeron